Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q3 FY2024
As of Mar 31, 2024
Q2 FY2024
As of Dec 31, 2023
Q1 FY2024
As of Sep 30, 2023
Q4 FY2023
As of Jun 30, 2023
Q3 FY2023
As of Mar 31, 2023
Q2 FY2023
As of Dec 31, 2022
Q1 FY2023
As of Sep 30, 2022
Q4 FY2022
As of Jun 30, 2022
Q3 FY2022
As of Mar 31, 2022
Q2 FY2022
As of Dec 31, 2021
Q1 FY2022
As of Sep 30, 2021
Q4 FY2021
As of Jun 30, 2021
Q3 FY2021
As of Mar 31, 2021
Q2 FY2021
As of Dec 31, 2020
Q1 FY2021
As of Sep 30, 2020
Q4 FY2020
As of Jun 30, 2020
Q3 FY2020
As of Mar 31, 2020
Q2 FY2020
As of Dec 31, 2019
Q1 FY2020
As of Sep 30, 2019
Q4 FY2019
As of Jun 30, 2019
Current assets
Cash and cash equivalents
Accounts receivable, net
Inventory
Other receivables, net
Advances to suppliers
Prepayments
Prepaid investment funds
Total current assets
Property, plants and equipment, net
Intangible assets, net
Construction in progress
Deferred tax assets
Total assets
Current liabilities
Short term loans
Accounts payable and accrued expenses
Other payables
Advances from customers
Related party debts
Related Party
Total related party debts
Wages payable
Taxes payable
Total current liabilities
Equity
Common stock, ($0.0001 par value per share, 300,000,000 shares authorized, 65,539,737 and 65,539,737 shares issued and outstanding as of March 31, 2024 and June 30, 2023, respectively)
Additional paid-in capital
Accumulated other comprehensive loss
Statutory reserves
Merger reserve
Retained earnings
Total stockholders’ (deficit)/equity
Total liabilities and equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support